References
- Go, Alan S., Dariush Mozaffarian, Veronique L. Roger, Emelia J. Benjamin, Jarett D. Berry, William B. Borden, et al. 2013. “Heart Disease and Stroke Statistics—2013 Update: A Report from the American Heart Association.” Circulation 127: 6–245.
- Ito, H., T. Tomooka, N. Sakai, H. Yu, Y. Higashino, K. Fujii, et al. 1992. “Lack of Myocardial Perfusion Immediately after Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction.” Circulation 85: 1699–1705.
- Niccoli, Giampaolo, Francesco Burzotta, Luca Galiuto, and Filippo Crea. 2009. “Myocardial No-Reflow in Humans.” Journal of the American College of Cardiology 54: 281–292.
- Rask Larsen, J., L. Dima, C. U. Correll, and P. Manu. 2018. “The Pharmacological Management of Metabolic Syndrome.” Expert Review of Clinical Pharmacology 11: 397–410.
- Caiazzo, G., R. L. Musci, L. Frediani, J. Umińska, W. Wanha, K. J. Filipiak, et al. 2020. “State of the Art: No-Reflow Phenomenon.” Cardiology Clinics 38: 563–573.
- Hassan, A. K., H. S. E. Mohamed, A. M. Mohamed, T. A. Ahmed, and Y. T. Kishk. 2018. “Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention: Thrombus Aspiration Was Protective.” The Egyptian Heart Journal 70: 421–426.
- Refaat, H., A. Tantawy, A. S. Gamal, and H. Radwan. 2021. “Novel Predictors and Adverse Long-Term Outcomes of No-Reflow Phenomenon in Patients with Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” Indian Heart Journal 73: 35–43.
- Elkammash, A., M. Sobhy, A. Zaki, and S. Ayad. 2022. “The Association between Admission Hyperglycaemia and the No-Reflow Phenomenon in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.” Future Healthcare Journal 9: 23.
- Tasar, O., A. K. Karabay, V. Oduncu, and C. Kirma. 2019. “Predictors and Outcomes of No-Reflow Phenomenon in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” Coronary Artery Disease 30: 270–276.
- Shakiba, M., A. Salari, F. Mirbolouk, N. Sotudeh, and S. Nikfarjam. 2020. “Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention.” The Journal of Tehran University Heart Center 15: 50.
- Mirbolouk, F., M. Gholipour, A. Salari, M. Shakiba, J. Kheyrkhah, V. Nikseresht, et al. 2018. “CHA2DS2-VASc Score Predicts No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention.” Journal of Cardiovascular and Thoracic Research 10: 46.
- Harrison, R. W., A. Aggarwal, F.-s. Ou, L. W. Klein, J. S. Rumsfeld, M. T. Roe, et al. 2013. “Incidence and Outcomes of No-Reflow Phenomenon during Percutaneous Coronary Intervention among Patients with Acute Myocardial Infarction.” The American Journal of Cardiology 111: 178–184.
- Ma, J., P Wu, S. Ma, X. Ma, P Jin, and S. Jia. 2024. “The Triglyceride–Glucose Index Is Associated with No-Reflow Phenomenon in STEMI Patients with Type 2 Diabetes after Percutaneous Coronary Intervention.” Frontiers in Cardiovascular Medicine 11: 1386318.
- Kim, M. C., J. Y. Cho, H. C. Jeong, K. H. Lee, K. H. Park, D. S. Sim, et al. 2016. “Long-Term Clinical Outcomes of Transient and Persistent No-Reflow Phenomena following Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.” Korean Circulation Journal 46: 490–498.
- Zhao, J., N. Li, S. Li, and J. Dou. 2025. “The Predictive Significance of the Triglyceride-Glucose Index in Forecasting Adverse Cardiovascular Events among Type 2 Diabetes Mellitus Patients with Co-Existing Hyperuricemia: A Retrospective Cohort Study.” Cardiovascular Diabetology 24: 218.
- Ma, J., M. Wang, P. Wu, X. Ma, D. Chen, S. Jia, et al. 2024. “Predictive Effect of Triglyceride-Glucose Index on No-Reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” Diabetology & Metabolic Syndrome 16: 67.
- Wang, G., C. Xu, J. Wang, Z. Teng, X. Sha, K. Xu, et al. 2025. “Triglyceride-Glucose Index Is Associated with Microcirculatory Resistance in Patients with Type 2 Diabetes and STEMI Undergoing Primary PCI.” Scientific Reports 15: 4723.
- Khalfallah, M., D. A. Maria, and A. Allaithy. 2022. “Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” Global Heart 17: 23.
- Mansour, H., A. Elabd, M. Ghazy, W. Sameer, I. Abdelhamid, and A. Tamara. 2021. “Clinical and Laboratory Predictors of No-Reflow during Primary Percutaneous Coronary Intervention.” Egyptian Journal of Hospital Medicine 83: 1022–1029.
- Krasniqi, X., J. Vincelj, D. Koçinaj, B. Berisha, and A. Bakalli. 2025. “Predictive Value of High-Sensitivity CRP Level on the No-Reflow Phenomenon in STEMI Patients.” Cardiology Research and Practice 2025: 1–7.
- Namazi, M., E. Mahmoudi, M. Safi, Y. Jenab, H. Vakili, H. Saadat, et al. 2021. “The No-Reflow Phenomenon: Is It Predictable by Demographic Factors and Routine Laboratory Data?” Acta Bio Medica: Atenei Parmensis 92.
- Asoglu, R., A. Afsin, E. Asoglu, and A. Suner. 2019. “Association between Platelet/Lymphocyte Ratio and Angiographic No-Reflow in Patients with Non-ST Segment Elevation Acute Myocardial Infarction Undergoing Primary Coronary Intervention.” International Journal of Clinical Cardiology 6: 159.
- Kuliczkowski, W., M. Gasior, D. Pres, J. Kaczmarski, A. Laszowska, M. Szewczyk, et al. 2015. “Aspirin ‘Resistance’: Impact on No-Reflow, Platelet and Inflammatory Biomarkers in Diabetics after ST-Segment Elevation Myocardial Infarction.” Cardiology 131: 41–50.
- Refaat, H., A. Tantawy, A. S. Gamal, and H. Radwan. 2021. “Novel Predictors and Adverse Long-Term Outcomes of No-Reflow Phenomenon in Patients with Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” Indian Heart Journal 73: 35–43.